SepsisFLUIDSNCT07009665
Fluid Management and Individualized Resuscitation in Sepsis
A study testing Personalized SV-guided resuscitation in people with Sepsis and Shock, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
The goal of this clinical trial is to find out if a personalized treatment approach can improve care for people with sepsis in the emergency department (ED). Sepsis is a life-threatening condition that happens when the body has an uncontrolled response to an infection. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sepsis, Shock, Personalized Medicine
- What is being tested?
- Personalized SV-guided resuscitation
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 188 participants
- Where
- 1 siteNetherlands
- Study dates
- 1 Sep 2025to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (≥ 18 years of age);
- Referred to internal medicine, nephrology, geriatric medicine, oncology, hematology, lung medicine, rheumatology, gastrointestinal / liver medicine, urology, or emergency medicine (non-trauma);
- Confirmed or suspected infection according to the physician's judgement upon arrival to the ED, based the presence of an acute phase response not due to an alternative non-infectious cause (i.e., body temperature < 36°C or >38°C, leukocyte count > 12 x109/L or C-reactive protein > 50 mg/L), and/or on symptoms suggestive for an infection (e.g. productive cough, dyspnea, dysuria, pollakisuria, abdominal pain, erythema)
- Need for hemodynamic resuscitation, based on any of the following (first measurement at ED arrival [triage]):
- Mean arterial pressure (MAP) < 70 mmHg
- Systolic blood pressure (SBP) < 90 mmHg or a SBP decrease >40 mmHg
Show all 9Show fewer
- Lactate > 4.0 mmol/L
- Shock index* > 0.9
- Enrolled in study within one hour after ED arrival
Who cannot join
- Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, drug overdose, or injury from burn or trauma, diabetic ketoacidosis, hyper-osmolarity syndrome, pancreatitis
- Known aortic insufficiency, aortic abnormalities, or intraventricular heart defect, such as ventral septal defect or atrial septal defect
- Known advanced heart failure - meaning NYHA IV functional class HF, on waiting list for heart transplant, LVAD recipient or chronic inotrope use.
- Known end-stage kidney disease (dialysis-dependent CKD stage 5 or eGFR <15 mL/min/1.73 m²)
- Decompensated liver cirrhosis at ED admission (e.g., ascites, hepatic encephalopathy, or variceal bleeding)
- Hemodynamic instability due to active bleeding
Show all 17Show fewer
- Patient has received >1 liter of IV fluid prior to study randomization
- Requires immediate surgery
- Transfer from another hospital after initiation of therapy (a.o. referred by another hospital ICU) or another in-hospital setting
- Pregnant women
- Trauma patients
- Suspected intra-abdominal hypertension, based on the presence of portal hypertension (i.e. presence of ascites due to liver cirrhosis, esophageal varices or as measured by Doppler ultrasound)
- Inability to obtain IV access
- Patient uncouples from treatment algorithm
- Patient should be excluded based on the opinion of the Clinician/Investigator
- Not able to commence treatment protocol within 1 hour after randomization
- Potential ICU-admission unwanted by advanced care directive (e.g., limited life expectancy)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sanne Ter Horst, MD contact
Netherlands1 site, 1 recruiting
- Recruiting
University Medical Centre Groningen
Groningen, Provincie Groningen, 9713GZ
Sanne Ter Horst, MD, +31 (0)50 361 6161, s.ter.horst@umcg.nl
Hjalmar R Bouma, MD, PhD, EuCP (PI), + 31 (0)50 361 6161 ext. HR Bouma, h.r.bouma@umcg.nl
About this study
The goal of this clinical trial is to find out if a personalized treatment approach can improve care for people with sepsis in the emergency department (ED).
Sepsis is a life-threatening condition that happens when the body has an uncontrolled response to an infection. This can lead to low blood pressure, organ failure, and death if not treated quickly. Right now, most people with sepsis receive a standard amount of fluids to raise their blood pressure. But this one-size-fits-all approach can lead to fluid overload and other complications. Because each person responds differently, this study will test whether a more personalized treatment-based on how the heart responds to fluids-can lead to safer and more effective care.
Read more
The study will include 188 adults who come to the ED at the University Medical Centre Groningen (UMCG) with suspected sepsis in need of hemodynamic resuscitation. Everyone in the study will receive fluids to support their blood pressure.
Participants will be randomly assigned to one of two groups:
- Personalized treatment group: Fluids and vasopressors (medications that raise blood pressure) will be given based on how the heart responds to each fluid dose. This response is measured using a non-invasive monitor that tracks stroke volume index (ΔSVI)-a measure of how much blood the heart pumps.
- Standard care group: Fluids will be given based on current guidelines (30 milliliters per kilogram of body weight), as decided by the treating doctor.
Researchers will compare how much fluid is given during the first 3 hours of care. They will also look at:
- When and how much vasopressor medicine is used
- How well blood pressure and circulation respond
- Signs of organ recovery or damage
- How long participants stay in the hospital
- Any problems or side effects during treatment
The researchers hope that this personalized approach will lead to using less fluid, starting vasopressors earlier, and helping people with sepsis recover more safely and quickly.
- Conditions
- Sepsis, Shock, Personalized Medicine, Emergency Medicine, Critical Care, Fluid Resuscitation, Fluid Responsiveness
- Being tested
- Personalized SV-guided resuscitation, Standard Care Resuscitation
- Keywords
- Sepsis, Shock, Personalized medicine, emergency medicine, critical care, fluid resuscitation, fluid responsiveness
- Medical subject headings
- Sepsis, Shock
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personalized SV-guided resuscitationOther
Participants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours.
Standard Care ResuscitationOther
In the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign).
| Study group | Role | What they receive |
|---|---|---|
| Personalized SV-Guided Resuscitation | Experimental | Not described Receives: Other: Personalized SV-guided resuscitation |
| Standard Care Resuscitation | Active comparator | Not described Receives: Other: Standard Care Resuscitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
The volume of IV fluids in ml administered within the first three hours after study enrolment.
The primary endpoint is the volume of IV fluids in ml administered within the first three hours after study enrolment.
Measured: Up to three hours, after study enrolment.
Secondary outcomes (22)
Length-of-stay in hospital/intensive care unit (ICU)
Length-of-stay in hospital and on intensive care unit (ICU) in days
Measured: Until hospital discharge, an average of 2 weeks
New onset organ failure
Any of the following within 48 hours:
- Rise in Sequential Organ Failure Assessment (SOFA) score of at least 2
- Organ support (i.e. vasopressor use [non-]invasive mechanical ventilation, acute dialysis, ECMO)
Measured: Up to 48 hours after hospitalization
Fluid balance
Net fluid balance calculated as the total volume of fluids administered (intravenous and oral, including prehospital) minus the total volume of fluid output (urine and other measurable losses) within the first three hours after ED presentation
Measured: Up to three hours after hospitalization
Fluid resuscitation
Volume of IV fluid resusciation within 7 days
Measured: Up to 7 days after hospitalization
Time to recovery of hemodynamic stability
Hemodynamic stability (HDS) is defined as MAP ≥ 70 mmHg, SBP ≥ 90 mmHg, lactate ≤ 4 mmol/L and SI ≤ 0.9.
Measured: The time interval from hospital admission until hemodynamic stability, measured in hours.
Pre-tibial edema development
Pre-tibial edema rise of ≥ 2 (grade 1-4), measured at triage, after 3h, 24h and 48h
Measured: Up to 48h after hospitalization
Fluid overload at three hours (assessed by Point-of-Care Ultrasound)
Venous congestion is assessed using Point-of-Care Ultrasound (PoCUS) at three hours after hospital admission. The PoCUS evaluation includes measurements of the Inferior Vena Cava (IVC), the Venous Excess Ultrasound (VExUS) score, and assessment following the Bedside Lung Ultrasound in Emergency (BLUE) protocol.
Measured: Up to three hours after hospitalization
Fluid overload at 24h (assessed by Point-of-Care Ultrasound)
Venous congestion is assessed using Point-of-Care Ultrasound (PoCUS) at 24 hours after hospital admission. The PoCUS evaluation includes measurements of the Inferior Vena Cava (IVC), the Venous Excess Ultrasound (VExUS) score, and assessment following the BLUE protocol.
Measured: Up to 24h after hospitalization
Loop diuretic use
Loop diuretic use will be determined daily and retrieved from the electronic health records (EHR) of the hospital, general practitioner, and pharmacy.
Measured: Up to 7 days after hospitalization
Decompensated heart failure
Occurrence of decompensated heart failure within 7 days after admission, as determined by the clinical judgment of the treating physician.
Measured: Up to 7 days after hospitalization
Respiratory insufficiency and acute respiratory distress syndrome (ARDS)
ARDS is defined as the presence of any of the following within 7 days after admission:
- PaO₂/FiO₂ ratio < 53 kPa
- Requirement for (non-)invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Measured: Up to 7 days after hospitalization
Acute Kidney Injury (AKI within 48 hours)
AKI is defined according to the KDIGO criteria and assessed within the first 48 hours after admission.
Measured: Up to 48 hours after hospitalization
Acute Kidney Injury (AKI within seven days)
AKI is defined according to the KDIGO criteria and assessed within the first seven days after admission.
Measured: Up to 7 days after hospitalization
Change in Serum Creatinine Levels (from Baseline to 48 Hours)
The difference in serum creatinine concentration measured at baseline and at 48 hours after admission.
Measured: From baseline to 48 hours
Change in Serum Creatinine Levels (from baseline to 7 days)
The difference in serum creatinine concentration measured at baseline and at 7 days after admission.
Measured: From baseline to 7 days
Requirement for renal replacement therapy (RRT) within 7 days
Initiation of renal replacement therapy (e.g., hemodialysis, continuous renal replacement therapy) within 7 days after hospital admission, as determined from electronic health care records.
Measured: Up to 7 days after hospitalization
Requirement for renal replacement therapy (RRT) within 30 days
Initiation of renal replacement therapy (e.g., hemodialysis, continuous renal replacement therapy) within 30 days after hospital admission, as determined from electronic health care records.
Measured: Up to 30 days after hospitalization
Major Adverse Cardiac Event (MACE)
Occurrence of any of the following events within 30 days after admission:
- Cardiovascular death
- Nonfatal myocardial infarction
- Nonfatal stroke
Measured: Up to 30 days
Vasopressor initiation within three hours
Start of vasopressor therapy within the first three hours after hospital admission.
Measured: Up to three hours
Vasopressor initiation within 7 days
Start of vasopressor therapy within the first 7 days after hospital admission.
Measured: Up to 7 days
Time to vasopressor initiation
The duration between hospital admission and the initiation of vasopressor treatment.
Measured: The time interval from hospital admission until the initiation of vasopressor therapy, measured in hours.
All-cause mortality (up to 30 days):
Mortality will be retrieved from the electronic health records (EHR) from the hospital and municipal registration. The cause of death will be retrieved from the EHR from the hospital.
Measured: Time from hospital admission until death from any cause, up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start1 Sep 2025
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SepsisStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 188 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hjalmar Bouma, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07009665
- Sponsor's protocol ID
- NL84833.099.24
- Acronym
- FLUIDS
- Status last verified
- Dec 2025
- First submitted
- 20 May 2025
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Ter Horst S, Ter Avest E, van Everdink J, van Meurs M, Olgers TJ, Vos JJ, Damman K, Ter Maaten JC, Bouma HR. FLUid management and InDividualized resuscitation in Sepsis (FLUIDS)-A Study protocol for a single-centre, open-label, randomized clinical trial. PLoS One. 2025 Dec 19;20(12):e0338504. doi: 10.1371/journal.pone.0338504. eCollection 2025.
PubMed 41417807
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fluid Management and Individualized Resuscitation in Sepsis
- ClinicalTrials.gov ID
- NCT07009665
- Acronym / sponsor ID
- FLUIDS / NL84833.099.24
- Conditions
- Sepsis, Shock, Personalized Medicine, Emergency Medicine, Critical Care, Fluid Resuscitation, Fluid Responsiveness
- Keywords
- Sepsis, Shock, Personalized medicine, emergency medicine, critical care, fluid resuscitation, fluid responsiveness
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 188 participants (estimated)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find out if a personalized treatment approach can improve care for people with sepsis in the emergency department (ED).
Sepsis is a life-threatening condition that happens when the body has an uncontrolled response to an infection. This can lead to low blood pressure, organ failure, and death if not treated quickly. Right now, most people with sepsis receive a standard amount of fluids to raise their blood pressure. But this one-size-fits-all approach can lead to fluid overload and other complications. Because each person responds differently, this study will test whether a more personalized treatment-based on how the heart responds to fluids-can lead to safer and more effective care.
The study will include 188 adults who come to the ED at the University Medical Centre Groningen (UMCG) with suspected sepsis in need of hemodynamic resuscitation. Everyone in the study will receive fluids to support their blood pressure.
Participants will be randomly assigned to one of two groups:
- Personalized treatment group: Fluids and vasopressors (medications that raise blood pressure) will be given based on how the heart responds to each fluid dose. This response is measured using a non-invasive monitor that tracks stroke volume index (ΔSVI)-a measure of how much blood the heart pumps.
- Standard care group: Fluids will be given based on current guidelines (30 milliliters per kilogram of body weight), as decided by the treating doctor.
Researchers will compare how much fluid is given during the first 3 hours of care. They will also look at:
- When and how much vasopressor medicine is used
- How well blood pressure and circulation respond
- Signs of organ recovery or damage
- How long participants stay in the hospital
- Any problems or side effects during treatment
The researchers hope that this personalized approach will lead to using less fluid, starting vasopressors earlier, and helping people with sepsis recover more safely and quickly.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Personalized SV-Guided Resuscitation | Experimental | Other: Personalized SV-guided resuscitation |
| Standard Care Resuscitation | Active comparator | Other: Standard Care Resuscitation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Adult patients (≥ 18 years of age);
- Referred to internal medicine, nephrology, geriatric medicine, oncology, hematology, lung medicine, rheumatology, gastrointestinal / liver medicine, urology, or emergency medicine (non-trauma);
- Confirmed or suspected infection according to the physician's judgement upon arrival to the ED, based the presence of an acute phase response not due to an alternative non-infectious cause (i.e., body temperature < 36°C or >38°C, leukocyte count > 12 x109/L or C-reactive protein > 50 mg/L), and/or on symptoms suggestive for an infection (e.g. productive cough, dyspnea, dysuria, pollakisuria, abdominal pain, erythema)
- Need for hemodynamic resuscitation, based on any of the following (first measurement at ED arrival [triage]):
- Mean arterial pressure (MAP) < 70 mmHg
Key exclusion criteria (17 listed)
- Primary diagnosis of: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, drug overdose, or injury from burn or trauma, diabetic ketoacidosis, hyper-osmolarity syndrome, pancreatitis
- Known aortic insufficiency, aortic abnormalities, or intraventricular heart defect, such as ventral septal defect or atrial septal defect
- Known advanced heart failure - meaning NYHA IV functional class HF, on waiting list for heart transplant, LVAD recipient or chronic inotrope use.
- Known end-stage kidney disease (dialysis-dependent CKD stage 5 or eGFR <15 mL/min/1.73 m²)
- Decompensated liver cirrhosis at ED admission (e.g., ascites, hepatic encephalopathy, or variceal bleeding)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Personalized SV-guided resuscitationParticipants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours. | Other | Personalized SV-Guided Resuscitation |
| Standard Care ResuscitationIn the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign). | Other | Standard Care Resuscitation |
Primary outcome
The volume of IV fluids in ml administered within the first three hours after study enrolment.
Time frame: Up to three hours, after study enrolment.
The primary endpoint is the volume of IV fluids in ml administered within the first three hours after study enrolment.
22 secondary outcomes
Length-of-stay in hospital/intensive care unit (ICU)
Time frame: Until hospital discharge, an average of 2 weeks
New onset organ failure
Time frame: Up to 48 hours after hospitalization
Fluid balance
Time frame: Up to three hours after hospitalization
Fluid resuscitation
Time frame: Up to 7 days after hospitalization
Time to recovery of hemodynamic stability
Time frame: The time interval from hospital admission until hemodynamic stability, measured in hours.
Pre-tibial edema development
Time frame: Up to 48h after hospitalization
Fluid overload at three hours (assessed by Point-of-Care Ultrasound)
Time frame: Up to three hours after hospitalization
Fluid overload at 24h (assessed by Point-of-Care Ultrasound)
Time frame: Up to 24h after hospitalization
Loop diuretic use
Time frame: Up to 7 days after hospitalization
Decompensated heart failure
Time frame: Up to 7 days after hospitalization
Respiratory insufficiency and acute respiratory distress syndrome (ARDS)
Time frame: Up to 7 days after hospitalization
Acute Kidney Injury (AKI within 48 hours)
Time frame: Up to 48 hours after hospitalization
Acute Kidney Injury (AKI within seven days)
Time frame: Up to 7 days after hospitalization
Change in Serum Creatinine Levels (from Baseline to 48 Hours)
Time frame: From baseline to 48 hours
Change in Serum Creatinine Levels (from baseline to 7 days)
Time frame: From baseline to 7 days
Requirement for renal replacement therapy (RRT) within 7 days
Time frame: Up to 7 days after hospitalization
Requirement for renal replacement therapy (RRT) within 30 days
Time frame: Up to 30 days after hospitalization
Major Adverse Cardiac Event (MACE)
Time frame: Up to 30 days
Vasopressor initiation within three hours
Time frame: Up to three hours
Vasopressor initiation within 7 days
Time frame: Up to 7 days
Time to vasopressor initiation
Time frame: The time interval from hospital admission until the initiation of vasopressor therapy, measured in hours.
All-cause mortality (up to 30 days):
Time frame: Time from hospital admission until death from any cause, up to 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Derived from this study: PubMed 41417807Ter Horst S, Ter Avest E, van Everdink J, van Meurs M, Olgers TJ, Vos JJ, Damman K, Ter Maaten JC, Bouma HR. FLUid management and InDividualized resuscitation in Sepsis (FLUIDS)-A Study protocol for a single-centre, open-label, randomized clinical trial. PLoS One. 2025 Dec 19;20(12):e0338504. doi: 10.1371/journal.pone.0338504. eCollection 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sanne Ter Horst, MD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Personalized SV-guided resuscitation in people with Sepsis and Shock, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sanne Ter Horst, MD (+31 6 25650284 (FLUIDS phone), s.ter.horst@umcg.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The volume of IV fluids in ml administered within the first three hours after study enrolment. (time frame: Up to three hours, after study enrolment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07009665, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.